Immix Biopharma is expected to report a Q3 2026 loss of $0.18 per share on zero revenue, with its current stock price of $7.26 trading significantly below the average analyst price target of $24.60.
Investors are primarily focused on clinical updates regarding NXC-201, the company's lead CAR-T therapy candidate for relapsed/refractory AL amyloidosis.
The market is looking for additional data from the NEXICART-2 trial following its recent selection for an oral presentation at the ASH 2026 conference. Furthermore, analysts will monitor the company's cash runway following a $125 million capital raise in September intended to fund operations through a planned BLA submission in 2027.